early results from a 3rd gen egfr-tki in advanced nsclc
Published 6 years ago • 237 plays • Length 2:51Download video MP4
Download video MP3
Similar videos
-
1:48
acquired resistance to third-generation egfr tkis in nsclc
-
3:12
egfr-tki therapy in advanced nsclc
-
20:35
tki-resistant egfr-mutant nsclc
-
0:53
ramalingam compares third generation egfr tki osimertinib to older agents in nsclc
-
6:14
third-generation egfr inhibitors in nsclc
-
8:30
third-generation egfr inhibitors in nsclc
-
4:48
third-generation egfr inhibitors in nsclc
-
21:09
mechanisms of resistance to egfr tki and new treatment strategies
-
9:25
tatton: updated results for patients with egfr-mutant positive nsclc
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
5:09
should a third generation egfr inhibitor be first line therapy for egfr mutation-positive nsclc?
-
3:48
azd9291, an egfr-tki, for t790m-mediated resistance in non-small cell lung cancer
-
2:36
second- and third-generation tkis in egfr-mutated nsclc
-
16:22
novel combinations in egfr positive advanced nsclc
-
16:16
managing patients with egfr exon 20 ins in nsclc and egfr tki toxicity
-
21:41
beyond erlotinib: are second generation egfr inhibitors better or simply newer?
-
15:35
asco 2020: latest developments in egfr-mutated non-small cell lung cancer
-
19:53
managing progression in egfr-mutant nsclc patients: potential impact of 2nd and 3rd generation tkis?
-
3:28
should third generation egfr inhibitors be used before or after progression?